First Racial-Ethnic Breast and Cervical Cancer Screening Data

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

WASHINGTON-A new analysis of data from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) shows that among women who received their first NBCCEDP Pap test between 1991 and 1998, American Indian and Alaskan Native (AI/AN) women had the highest proportion of abnormal Pap tests, while white women had the highest rate of serious cervical lesions detected by biopsy.

WASHINGTON—A new analysis of data from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) shows that among women who received their first NBCCEDP Pap test between 1991 and 1998, American Indian and Alaskan Native (AI/AN) women had the highest proportion of abnormal Pap tests, while white women had the highest rate of serious cervical lesions detected by biopsy.

Specifically, 4.4% of AI/AN women, 3.2% of blacks, 3.0% of whites, 2.7% of Hispanics, and 1.9% of Asian and Pacific Islanders (A/PIs) had abnormal tests. Biopsies detected serious cervical lesions in 9.9 per 1,000 Pap tests among whites, followed by Hispanics with 7.6 per 1,000, blacks at 7.1 per 1,000, AI/AN women with 6.7 per 1,000, and A/PIs at 5.4 per 1,000 Pap tests.

AI/AN women were the least likely to have ever had a Pap test prior to participating in a NBCCEDP screening. Black women were the least likely to receive follow-up care after a diagnosis of a serious cervical lesion.

NBCCEDP, which is administered by the CDC, is a federally funded program that provides breast and cervical cancer screenings to older and low-income women, and underserved women of racial and ethnic minority groups.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content